Lara Goldstein - Spark Newswire

3 minute read

Oregon Psychedelics Companies Set The Stage For Future Regulations Of Natural Medicine Centers

Today, 10:13 PM

Silo Wellness (OTCQB: SILFF) aims to establish a psilocybin center retreat in the New Frontier Ranch in Jackson County seems closer to becoming a reality.

SILFF

3 minute read

Psychedelics And Treatment-Resistant Depression: Reactions To COMPASS’ Published Results

By Lara Goldstein

Today, 10:13 PM

(Part two of a four-part series) See previous story in this series: Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS’ Latest Trial Outcomes

CMPS

2 minute read

Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial

By Lara Goldstein

Today, 10:13 PM

Psychedelics company Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Science Inc. has entered into a research services agreement with Canadian-based biotech Nova Mentis Life Science Corp.

KONEF

2 minute read

Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS’ Latest Trial Outcomes

By Lara Goldstein

Today, 10:13 PM

(Part one of a four-part series)

CMPS

2 minute read

Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon

By Lara Goldstein

Today, 10:13 PM

Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc.

AGNPF

2 minute read

Biomind Labs: Q3 Financials & FDA Approval For New Chemical Entity Targeting Treatment-Resistant Depression

By Lara Goldstein

Today, 10:13 PM

Next-gen psychedelics developer Biomind Labs Inc.

BMNDF

1 minute read

This Psychedelics Company Begins Trading On NASDAQ With $7.5M Offering Then Reverse Stock Split

By Lara Goldstein

Today, 10:13 PM

Psychedelics biotech firm Clearmind Medicine Inc.

CMND

2 minute read

Cybin Shares Q2 Financial & Business Results, Focus On Licensing Deals For Preclinical Assets

By Lara Goldstein

Today, 10:13 PM

Cybin Inc. (NYSE: CYBN) reported its unaudited financial results for its second quarter ended September 30, 2022, and provided business highlights for the period.

CYBN

2 minute read

Mydecine’s Q3 Financials & Update, Sustained Target On Smoking Cessation For Next 12 Months

By Lara Goldstein

Today, 10:13 PM

Mydecine Innovations Group (OTC: MYCOF), the psychedelics biotech company headquartered in Denver, Colorado with international offices in the Netherlands, reported its financial results and business highlights for the three and nine months ended September 30, 2022.

MYCOF